Answers are grounded in this paper and cite their sources.
Sir, Carbapenem-resistant Gram-negative bacteria represent an emerging threat to the management of hospital-acquired infections.1 Recently, Klebsiella pneumoniae carbapenemase (KPC)-producing Enterobacteriaceae strains have been reported worldwide.1 In China, KPC-producing Enterobacteriaceae strains are widely distributed nationwide, particularly in Zhejiang Province.2,3 This report confirms, to our knowledge for the first time, the arrival of KPC-2-producing K. pneumoniae in Taiwan. A middle-aged man, who did business in Zhejiang Province in China, was admitted to the intensive care unit (ICU) in a hospital in Zhejiang after successful resuscitation for cardiac arrest due to an unknown cause in 2010. He developed a sustained fever, together with leucocytosis, thrombocytopenia and anaemia after resuscitation. Empirical antibiotic therapy with cefoperazone/sulbactam was given. Three days after admission he was transferred to the medical ICU at National Taiwan University Hospital (NTUH). On admission to NTUH, the patient was in a deep coma and put on a ventilator. His body temperature was 38.2°C. Laboratory examinations revealed leucocytosis, anaemia, thrombocytopenia and abnormal renal and liver function. Chest radiography initially did not show a pneumonia patch on the first hospital day. Intermittent haemodialysis was performed for acute renal injury. Intravenous ceftriaxone (1 g every 12 h) was given empirically. However, fever persisted along with increased purulent sputum production. Chest radiography on the third hospital day showed consolidation in the right lower lobe. Ventilator-associated pneumonia was suspected and intravenous colistin (1.3 MU daily) was given empirically because the sputum culture obtained on the first hospital day yielded imipenem-resistant and colistin-susceptible Pseudomonas aeruginosa. The blood culture (isolate A) and sputum culture (isolate B) obtained on the third hospital day both grew imipenem-resistant K. pneumoniae. Cultures of an anal swab (isolate C) on the fifth hospital day also grew imipenem-resistant K. pneumoniae. On the 10th hospital day, the patient developed acute, left-side otitis externa, with purulent otorrhoea. The pus culture from the left ear also yielded imipenem-resistant K. pneumoniae (isolate D). The patient received vancomycin for 14 days due to suspected concurrent methicillin-resistant Staphylococcus aureus pneumonia and colistin for 21 days and recovered well on continuous ventilator and haemodialysis support. All four carbapenem-resistant K. pneumoniae isolates (isolates A to D) were positive for the modified Hodge test using imipenem and ertapenem discs.4,5 PFGE profiles of XbaI-digested genomic DNAs from the four isolates were identical. All four isolates of carbapenem-resistant K. pneumoniae harboured a blaKPC-2 gene [accession number GQ086225.1; identity 100% (750/750)], but did not have blaVIM and blaIMP genes.2 The blaKPC-2-containing plasmid could be detected from electrotransformation of Escherichia coli DH5α.6 All four isolates exhibited high MICs of four carbapenems (64–≥256 mg/L) but were susceptible to colistin (1–2 mg/L) and tigecycline (1 mg/L) using the broth microdilution method (Table 1).5 The electrotransformation of E. coli DH5α resulted in the following MICs: imipenem, 1 mg/L; meropenem, 2 mg/L; doripenem, 0.5 mg/L; and ertapenem, 2 mg/L. These findings were in accordance with those previously reported.6 All four isolates did not belong to serotypes K1, K2, K5, K20, K54, K57 or N1.7 MICs of 10 antimicrobial agents for the four KPC-2-producing K. pneumoniae isolates, the electrotransformant of E. coli DH5α and E. coli DH5α, determined using the broth microdilution method MICs of 10 antimicrobial agents for the four KPC-2-producing K. pneumoniae isolates, the electrotransformant of E. coli DH5α and E. coli DH5α, determined using the broth microdilution method A total of seven anal swabs collected from seven patients hospitalized in the same ICU and sputum and anal swabs obtained from the patient 14 days after the isolation of the KPC-2-producing K. pneumoniae were negative for KPC-2-producing K. pneumoniae. We report the first case of severe infection (ventilator-associated bacteraemic pneumonia and otitis externa) due to KPC-2-producing K. pneumoniae in a businessman working in Zhejiang Province, the epicentre of the KPC-2 endemic in China.1–3 This case suggests that infections due to KPC-producing K. pneumoniae could become an emerging problem in Taiwan, particularly given the frequency of travel between Taiwan and China in recent years. The optimal treatment for KPC-producing isolates is unknown.8 Although in vitro activity of tigecycline against KPC-producing K. pneumoniae is reported, tigecycline is not suitable for bloodstream infections due to its low serum concentrations.8 Colistin is another therapeutic option, but reduced susceptibility to colistin in KPC-producing K. pneumoniae has been reported.8 In our patient, colistin alone successfully eradicated KPC-2-producing K. pneumoniae in the bloodstream, respiratory tract and external ear, but exerted limited effect on clearance of the colistin-susceptible P. aeruginosa isolates. In conclusion, we report the first case of ventilator-associated bacteraemic pneumonia caused by KPC-2-producing K. pneumoniae in Taiwan. Although carbapenemase resistance in K. pneumoniae is currently rare in Taiwan, it could be an emerging problem in the future, and continued antimicrobial resistance surveillance is needed. This study was carried out as part of our routine work. None to declare.
No takes yet. Share an insight, caveat, or question.
Chung et al. (2011) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: